Informações:
Falhas:
ID
13808
Descrição
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01352650
Link
https://clinicaltrials.gov/show/NCT01352650
Palavras-chave
Versões (1)
- 07/03/2016 07/03/2016 -
Titular dos direitos
CC BY-NC 3.0
Transferido a
7 de março de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Acute Myeloid Leukemia NCT01352650
Eligibility Acute Myeloid Leukemia NCT01352650
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01352650
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
AML
Item
unequivocal pathologic diagnosis of aml (≥ 20% blasts in the bone marrow based on who criteria) excluding: i) acute promyelocytic leukemia t(15;17)(q22;q12); pml-rara; ii)acute myeloid leukemia with t(8;21)(q22;q22); runx1-runxt1; iii) acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); cbfb-myh11.
boolean
C0023467 (UMLS CUI [1])
C0023487 (UMLS CUI [2])
C0023487 (UMLS CUI [2])
AML
Item
aml patients with an antecedent hematologic disorder or myelodysplastic syndrome (mds)are eligible for treatment on this trial provided that they have not received prior treatment with decitabine or prior cytotoxic treatment for aml.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0049065 (UMLS CUI [3])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0049065 (UMLS CUI [3])
therapy-related myeloid neoplasms
Item
aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for >6 months.
boolean
C2939461 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
age
Item
age ≥ 60 years.
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
ability to understand and willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
prior treatment with decitabine
Item
prior treatment with decitabine
boolean
C0049065 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,2])
prior treatment with plerixafor
Item
prior treatment with plerixafor
boolean
C1955474 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,2])
concurrent therapy for another malignancy
Item
ongoing treatment for another malignancy.
boolean
C0006826 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
molecular or cytogenetics features
Item
patients with good-risk molecular or cytogenetics features
boolean
C0010802 (UMLS CUI [1])
C1521991 (UMLS CUI [2])
C1521991 (UMLS CUI [2])
comorbidity limiting study protocol
Item
patient has a medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
comorbidity limiting consent and completion
Item
patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
compliance behaviour
Item
patient has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements.
boolean
C1321605 (UMLS CUI [1])